Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soterios Pharma Reports Positive Phase II Results for STS-01 in Alopecia Areata
Details : STS-01 is a topical formulation which works by modulating cytokines, it is under development for the treatment of mild / moderate alopecia areata.
Product Name : STS-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Soterios Pharma completes Phase II Enrolment for STS-01 in Mild / Moderate (patchy) Alopecia Areata
Details : STS-01 is a cytokine modulator that modulates the inflammatory response and the proliferation of T-cells by disruption of the signalling pathways. It is under phase 2 clinical development for the treatment of mild / moderate (patchy) alopecia areata.
Product Name : STS-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2023
Lead Product(s) : STS-01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
